Juniper Pharmaceuticals Announces Listing on the NASDAQ Global Select Market

BOSTON, Oct. 20, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health specialty pharmaceutical company, announced that its common stock will begin trading on the Nasdaq Global Select Market, effective at market open today. The Company's symbol (JNP) will remain the same.

"We are proud to have fully satisfied the financial and liquidity requirements for listing on the Nasdaq Global Select Market, which we believe will improve the visibility of our stock and provide us with greater exposure to a broader base of institutional investors," said Frank Condella, Juniper's CEO. "This achievement reflects the execution of our strategy to build long-term value for shareholders from our core operations and through the development of an expanded product portfolio."

The Nasdaq Global Select Market states that it has the highest initial listing standards of any exchange in the world, with measures including market value, liquidity and earnings requirements. The Company's shares were previously listed on the Nasdaq Capital Market.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health.  Juniper has a commercial product,  CRINONE^® 8% (progesterone gel), which is marketed by Allergan, Inc. in the U.S. and by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide. The Company is advancing a pipeline of proprietary drug candidates leveraging novel delivery technologies.  Please visit www.juniperpharma.com for more information.

Juniper Pharmaceuticals™ and Juniper Pharma Services™ are trademarks of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE^® is a registered trademark of Allergan, Inc. in the U.S. and of Merck KGaA, Darmstadt, Germany, outside the U.S.

Forward Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are usually indicated by the words "may," "will," "plans," "believes," "expects," "anticipates," "potential," "should," or similar expressions, and which are generally not historical in nature. These include all statements relating to the expected benefits of listing on the NASDAQ Global Select Market.  Management believes that these forward-looking statements are reasonable as and when made.  However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Juniper Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.  For a discussion of certain risks and uncertainties associated with Juniper Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2014.  

Contact
Amy Raskopf 
Director, Corporate Communications
Juniper Pharmaceuticals, Inc.
(917) 673-5775
[email protected]

Follow us on LinkedIn

SOURCE Juniper Pharmaceuticals, Inc.

Related Links

http://www.juniperpharma.com